Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
58 hedge funds and large institutions have $64.4M invested in Dova Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 17 closing their positions.
8% less funds holding
Funds holding: 63 → 58 (-5)
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
71% less capital invested
Capital invested by funds: $220M → $64.4M (-$155M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$5.66M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.05M |
| 3 |
SIM
Spark Investment Management
New York
|
+$984K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$638K |
| 5 |
Squarepoint
New York
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$21.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.09M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.87M |
| 4 |
EU
Emory University
Atlanta,
Georgia
|
-$2.44M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.28M |
DOVA Hedge Fund Activity: Q4 2018 in Review
58 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q4 2018, worth a combined $64.4M — down 71% from $220M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of DOVA and 12 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 15 added.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $5.66M. The largest seller was Nexthera Capital, exiting entirely with an estimated $21.5M sold.
- 58 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q4 2018, down from 63 in Q3 2018.
- Funds reported $64.4M of Dova Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 71% quarter-over-quarter.
- 12 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 17 closed out, a net change of -5 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Broadfin Capital, an estimated $5.66M added.
- The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Nexthera Capital, an estimated $21.5M sold.
Based on aggregated 13F filings for Q4 2018.